Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Neuroone Medical Technologies (NMTC) Amortizatization of Intangibles (2016 - 2023)

Neuroone Medical Technologies filings provide 5 years of Amortizatization of Intangibles readings, the most recent being $4568.0 for Q2 2023.

On a quarterly basis, Amortizatization of Intangibles changed N/A to $4568.0 in Q2 2023 year-over-year; TTM through Sep 2023 was $45571.0, a N/A change, with the full-year FY2023 number at $45571.0, up 297.27% from a year prior.
Amortizatization of Intangibles hit $4568.0 in Q2 2023 for Neuroone Medical Technologies, down from $20238.0 in the prior quarter.
In the past five years, Amortizatization of Intangibles ranged from a high of $20765.0 in Q4 2022 to a low of $4568.0 in Q2 2023.